
ActivSignal LLC Profile last edited on: 7/18/19
CAGE: 7XHV2
UEI: XK3QGNFL2DE4
Business Identifier: Novel insights into signaling pathway activation Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 05
County: Middlesex
Congr. District: 05
County: Middlesex
Public Profile
ActivSignal LLC is structured around transforming technology into systems biology proteomics tools. For researchers working in the biotech space, the firm is offering a proprietary technology inexpensively providing novel insights into signaling pathway activation. The firm's lead product is the IPAD assay (Immuno-Paired-Antibody Detection assay): research tool for analyzing the activity of multiple signaling pathways in one reaction. Developed to enable researchers to understand the pathway activation / inhibition profile of cells, activities of multiple signaling pathways are assessed simultaneously in a single well through the measurement of 70 target human proteins for modifications, cleavage and expression. Each pathway is covered by multiple targets: easily scalable to 96-well format; highly sensitive, requiring small amount of sample for assay.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 2 | NSF | $1,624,998 | |
Project Title: ActivSignal Protein Profiling from Serum Exosomes for the Early Detection of Pancreatic Cancer |
Key People / Management
Ilya Alexandrov
Robert Glazer
Malcolm Mackenzie
Robert Glazer
Malcolm Mackenzie
Company News
There are no news available.